Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Highlights include: In SUMMIT, a registration-directed, global, randomized, placebo-controlled trial in patients with NonAdvSM, treatment with 100 mg bezuclastinib demonstrated: 56% mean improvement ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

High-risk patients in this arm also received 100 mg/m² of IV cisplatin every 3 weeks for 3 cycles ... All of the secondary end points were stratified by PD-L1 CPS status. 1 Merck’s Keytruda ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

If you’ve searched for places to buy Viagra online, you’ve surely also noticed its price tag. Since Viagra is a brand-name medication, the price of Viagra is very high and may not currently ...

The firm believes the “real culprit” for Merck shares remaining under pressure is Keytruda’s 2028 patent expiration. Despite the company building out its pipeline, past precedence shows the ...